publication venue for
- Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. 10:e003923-e003923. 2022
- Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. 10:e004335-e004335. 2022
- CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. 10:e003289-e003289. 2022
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. 10:e003024-e003024. 2022
- Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. 10:e003497-e003497. 2022
- CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. 9:e003329-e003329. 2021
- Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy. 9:e001933-e001933. 2021
- Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. 8:e000981-e000981. 2020
- Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. 8:e000371-e000371. 2020
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. 8:e000337-e000337. 2020
- Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. 7:189. 2019
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. 6:5. 2018
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 5:66. 2017
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. 4:1-106. 2016
- Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. 3:55. 2015
- On-target off-tumor toxicity; when enhancing an NKG2D-based CAR in vitro led to severe toxicities in vivo. 2:P15-P15. 2014
- Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors. 2:P17-P17. 2014
- Conditional immune toxicity rate with immune checkpoint inhibitors 2019
- A novel chimeric T cell receptor that operates through the endogenous TCR diverges in biology from conventional CAR T cells 2017
- Preclinical evaluation of BCMA-specific TAC receptor-engineered T cells for multiple myeloma 2017